While targeting PRMT5 presents a therapeutic strategy for MTAP-deficient tumors, these findings highlight the potential immunosuppressive side effects on T cell responses, underscoring the need for careful evaluation of immune system impacts in cancer therapy development [95]. This evidence concerns the gene MTAP and cancer.